Bob Risoleo is the General Counsel of MPM as well as of BioImpact Capital, an affiliate manager of MPM and manager of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities.
Prior to joining MPM and BioImpact Capital, Bob spent 35 years at the global law firm Sullivan and Cromwell LLP where he served as a trusted advisor to clients who relied on him to handle novel and complex transactions, including in the areas of capital markets, structured and leveraged finance, M&A, joint ventures, and corporate restructuring. Known for his deep curiosity and ability to ask incisive questions, Bob has succeeded in helping U.S. and foreign companies, sovereign governments, and multilateral institutions secure high impact outcomes in some of their most critical transactional, governance, risk management and compliance matters.
Bob received his J.D. from Yale Law School and his B.A. from Yale College. Before joining Sullivan & Cromwell, Bob served as a law clerk to Judge Edward R. Becker on the United States Court of Appeals.
Brendan is the Chief Compliance Officer of MPM Capital and BioImpact Capital, an affiliate manager of MPM and manager of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities. Prior to joining MPM Capital and BioImpact Capital, Brendan served as a Senior Principal Consultant at ACA Group specializing in supporting hedge, private equity, and venture capital funds to develop and administer custom compliance programs. Before ACA Group, Brendan had several legal and compliance roles with AdvisorAssist, a boutique investment adviser consulting firm and American Student Assistance. Brendan began his compliance career at Key Bank developing a customer identification program/KYC process.
Brendan has a Bachelor of Arts in Communications and Philosophy from the University of Delaware and a JD from Suffolk University Law School. Brendan is a licensed attorney with the Commonwealth of Massachusetts.
Dr. Florencia Pereyra Segal is a Partner at BioImpact Capital, an affiliate manager of MPM.
Florencia is an Infectious Diseases physician-scientist and drug development leader. Prior to joining BioImpact, Florencia was the Global Head of Translational Medicine for Global Health at Novartis, during which time she and her team lead the early development of a broad portfolio, including small molecules and biologics for the treatment of viruses, bacteria, and parasites. Prior to her time in industry Florencia was a Principal Investigator leading translational and laboratory research focused on HIV immunology at the Ragon Institute of MGH, MIT and Harvard.
Florencia earned her M.D. with honors at the Universidad Central de Venezuela and completed her specialty Infectious Diseases and post-doctoral training at Brigham and Women’s and Massachusetts General Hospital. She remains a faculty member and associate physician at the Division of Infectious Diseases at Brigham and Women’s Hospital where she has practiced for over 15 years.
Dr. Emily Gaudiano is responsible for investment identification, due diligence, business development, and company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM. Emily joined MPM full time in 2022 after completing an internship with the firm, where she supported diligence efforts for MPM newco Aktis Oncology and surveyed incoming deal flow for investment opportunities.
Prior to joining MPM and BioImpact Capital, Emily was recently awarded her Ph.D. in Chemical Biology at Harvard Medical School under advisor Arlene Sharpe. Her thesis focused on characterizing novel signaling mechanisms of co-inhibitory receptor PD-1 in tumor infiltrating lymphocytes. In addition to her academic research, Emily served as a director on the leadership team of the GSAS Harvard Biotech Club and has been involved in a variety of community outreach programs across Boston to address healthcare disparities.
Emily received her B.S. in Biochemistry from Boston College.
Dr. Rami Rahal is responsible for investment identification and due diligence for BioImpact Capital, an affiliate manager of MPM.
Prior to joining BioImpact Capital, Rami spent the majority of his career in drug discovery prosecuting multiple target classes for both precision oncology and immunotherapy. Most recently, he was a Senior Director of Cancer Biology at Scorpion Therapeutics where he joined as the first biologist and played pivotal roles in expanding the biology drug discovery team, research infrastructure, and early portfolio. Before joining Scorpion Therapeutics, Rami was at KSQ Therapeutics, where he led multiple small molecule drug discovery programs for novel IO targets and helped build an integrative IO drug discovery strategy. Rami began his career in biotech at Blueprint Medicines where he served as the lead biologist for the RET inhibitor program (BLU-667/Pralsetinib) from early optimization into Phase 1. Pralsetinib is now an FDA approved medicine (Gavreto) for RET-driven metastatic NSCLC and medullary thyroid cancer.
Rami earned his PhD in Genetics from MIT and conducted postdoctoral fellowships at Harvard Medical School and the Novartis Institutes of Biomedical Research (NIBR). At NIBR, he leveraged pharmacological and genomic profiling to identify new treatment strategies for mantle cell lymphoma and characterized novel synthetic lethal cancer vulnerabilities. His work has been highlighted in Cancer Cell, Cancer Discovery, and Nature Reviews Cancer.
Dr. Alim Ladha is responsible for investment identification, due diligence, business development, and company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM.
Prior to joining MPM and BioImpact Capital, Alim completed his Ph.D. in Biological Engineering at the Massachusetts Institute of Technology (MIT) in Feng Zhang’s lab at the Broad Institute where he focused on developing new molecular tools for biotechnology including CRISPR-associated transposases, retroelement based genome insertion methods, novel nucleic acid delivery vehicles, and CRISPR-based diagnostics. Prior to MIT, Alim worked on the development of microbiome-based therapeutics at Finch Therapeutics and OpenBiome.
Alim received his B.S.E., summa cum laude, in Biomedical Engineering from Duke University.
Dr. Uciane Scarlett is responsible for investment identification, due diligence, business development and new company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM. Uciane currently serves on the board of a newly formed, stealth portfolio company.
Prior to joining MPM and BioImpact Capital, Uciane was a Principal at Oxford Sciences Enterprise (OSI, UK), an Oxford-affiliated firm, where she initially co-led the life science sector. While at OSE, Uciane led financings and drove company creation efforts for several companies including T-Cypher Bio, where she served as interim Executive Chair, Alethiomics, PepGen and Endlyz. She represented OSE on the boards of T-Cypher, PepGen, Miro Bio, Scenic Bio, and DJS. Prior to OSE, Uciane was on the investment team at Atlas Venture where she drove company creation, operations, and financings activities for Dyne Therapeutics (DYN) and Quench Bio and served in operational roles for AVROBIO (AVRO) and KorroBio. Uciane was the Director of BD & Strategy at Compass Therapeutics prior to Atlas.
Uciane holds a Ph.D. in cancer immunology from Dartmouth College. She received her BSc, first-class honors, in biotechnology (major) and zoology (minor) from the University of the West Indies.
Christian Desmarteaux is the Director of Investor Relations for BioImpact Equities (f/k/a Burrage Capital) and is responsible for coordinating all efforts relating to both existing and prospective investor relations.
Prior to joining Burrage Capital, Christian was an Account Executive at Turbonomic, a Boston based technology firm that is a global leader in business application performance. Prior to that, he worked as a Sales Consultant raising capital for several privately held companies in North America to help them achieve strategic business development and capital milestones.
Christian earned his M.B.A. from Northeastern University D’Amore-McKim School of Business and his B.S. in Communication/Business Administration from St. John’s University.
Dr. Terri Lee is responsible for investment identification, due diligence, company formation and business development activities at MPM. Terri has led diligence and supported multiple MPM investments, including Arialys, Photys (Board Observer), and Protego. Currently, Terri serves in strategic operational roles at BioIntervene and at a newly formed, stealth MPM startup company.
Terri received her Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, where her thesis focused on the role of actin nucleators in DNA repair pathways. In addition to academic research, Terri worked on identifying commercial opportunities and company formation at the Gladstone Institutes, including taking on an operations role at a therapeutics company in the neurodegenerative space.
Terri received her B.S. in Pharmacology and Microbiology from the University of California, Santa Barbara.
Kellie Neville is the Director of Investor Relations at MPM Capital. She joins MPM’s Managing Directors in building lasting relationships with its Limited Partners. Kellie also leads MPM’s communications and marketing efforts.
Prior to joining MPM, Kellie was Director of Investor Relations & Marketing at 424 Capital, a boutique private equity investor, where she was responsible for raising capital, investor relationships and product development. Prior to that, Kellie was a Senior Investor Relations Associate at TA Associates, a middle market growth equity partner, supporting the firm’s fundraising efforts and ongoing Limited Partner relationships.
Kellie earned her B.A. in Public Relations and Marketing Communications from Simmons University.